“This book will be certainly a valuable reference source for all those who are interested in antiviral drug discovery. All of the information contained in this text offers a rich scientific support for researchers in academia and industry at any level who are interested in enhancing their knowledge on a very fascinating scientific topic.” (ChemMedChem, 2012)
Provides the Foundation Needed to Design Effective HIV-1 Integrase Inhibitors
Around the world, scientists have been working for years with the goal of designing effective HIV-1 integrase inhibitors in the battle against AIDS. This book reviews all their latest research findings on both inhibitor design and the mechanisms of action of HIV-1 integrase. Chapters have been contributed by leading pioneers in the field from North America, Europe, and Asia. These contributions represent not only a thorough review of the current literature, but also the authors’ firsthand experience in drug development and design. Coverage includes such topics as:
-
Integrase mechanism, structure, and function
-
HIV-1 integraseDNA interaction
-
Host factors affecting provirus stability and silencing
-
Role of metals in HIV-1 integrase inhibitor design
-
Historic perspectives, challenges, and future opportunities
As the first publication to comprehensively examine HIV-1 integrase, this book is essential reading for anyone involved in inhibitor drug discovery.
-
Integrates chemical, biochemical, and biological approaches, enabling readers to take full advantage of a promising target enzyme for combating HIV and retroviruses
-
Illustrates rational drug design for a complex drug target with plenty of step-by-step examples
-
Addresses drug design issues from a variety of perspectives to help readers understand both the challenges and opportunities of developing a successful HIV-1 integrase inhibitor
This book fills an important gap in the review literature, offering a valuable introduction to the field for scientists who need to collaborate with researchers in several disciplines in order to design drugs that effectively target HIV-1 integrase.
From the Back Cover
Provides the Foundation Needed to Design Effective HIV-1 Integrase Inhibitors
Around the world, scientists have been working for years with the goal of designing effective HIV-1 integrase inhibitors in the battle against AIDS. This book reviews all their latest research findings on both inhibitor design and the mechanisms of action of HIV-1 integrase. Chapters have been contributed by leading pioneers in the field from North America, Europe, and Asia. These contributions represent not only a thorough review of the current literature, but also the authors’ firsthand experience in drug development and design. Coverage includes such topics as:
-
Integrase mechanism, structure, and function
-
HIV-1 integrase DNA interaction
-
Host factors affecting provirus stability and silencing
-
Role of metals in HIV-1 integrase inhibitor design
-
Historic perspectives, challenges, and future opportunities
As the first publication to comprehensively examine HIV-1 integrase, this book is essential reading for anyone involved in inhibitor drug discovery.
-
Integrates chemical, biochemical, and biological approaches, enabling readers to take full advantage of a promising target enzyme for combating HIV and retroviruses
-
Illustrates rational drug design for a complex drug target with plenty of step-by-step examples
-
Addresses drug design issues from a variety of perspectives to help readers understand both the challenges and opportunities of developing a successful HIV-1 integrase inhibitor
This book fills an important gap in the review literature, offering a valuable introduction to the field for scientists who need to collaborate with researchers in several disciplines in order to design drugs that effectively target HIV-1 integrase.
About the Author
Nouri Neamati, PhD, is an Associate Professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California School of Pharmacy. He is the recipient of numerous awards and has published more than 170 peer-reviewed manuscripts, several book chapters, and patents in the area of drug design and discovery. Dr. Neamati is the Editor-in-Chief of Current Molecular Pharmacology; an Associate Editor of Current Cancer Drug Targets; and an Editorial Advisory Board member of several journals including Expert Opinion on Drug Discovery, Expert Opinion on Investigational Drugs, and Hormones & Cancer.
Wow! eBook
